Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4390941
Author(s) Keller, Xavier E.; Kardas, Piotr; Acevedo, Claudio; Sais, Giovanni; Poyet, Cédric; Banzola, Irina; Mortezavi, Ashkan; Seifert, Burkhardt; Sulser, Tullio; Hirsch, Hans H.; Provenzano, Maurizio
Author(s) at UniBasel Hirsch, Hans H.
Year 2015
Title Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer
Journal Oncotarget
Volume 6
Number 8
Pages / Article-Number 6459-69
Keywords Antibody Formation; BK Virus/*immunology; Humans; Male; Middle Aged; Polyomavirus Infections/*immunology; Prognosis; Prospective Studies; Prostatic Neoplasms/*immunology/pathology/*virology; BK polyomavirus; antibody response; biochemical recurrence; prostate cancer
Mesh terms Antibody Formation; BK Virus, immunology; Humans; Male; Middle Aged; Polyomavirus Infections, immunology; Prognosis; Prospective Studies; Prostatic Neoplasms, virology
Abstract Infectious agents, including the BK polyomavirus (BKPyV), have been proposed as important inflammatory pathogens in prostate cancer. Here, we evaluated whether the preoperative antibody response to BKPyV large T antigen (LTag) and viral capsid protein 1 (VP1) was associated with the risk of biochemical recurrence in 226 patients undergoing radical prostatectomy for primary prostate cancer. Essentially, the multivariate Cox regression analysis revealed that preoperative seropositivity to BKPyV LTag significantly reduced the risk of biochemical recurrence, independently of established predictors of biochemical recurrence such as tumor stage, Gleason score and surgical margin status. The predictive accuracy of the regression model was denotatively increased by the inclusion of the BKPyV LTag serostatus. In contrast, the VP1 serostatus was of no prognostic value. Finally, the BKPyV LTag serostatus was associated with a peculiar cytokine gene expression profile upon assessment of the cellular immune response elicited by LTag. Taken together, our findings suggest that the BKPyV LTag serology may serve as a prognostic factor in prostate cancer. If validated in additional studies, this biomarker may allow for better treatment decisions after radical prostatectomy. Finally, the favorable outcome of LTag seropositive patients may provide a potential opportunity for novel therapeutic approaches targeting a viral antigen.
Publisher IMPACT JOURNALS LLC
ISSN/ISBN 1949-2553 (Electronic) 1949-2553 (Linking)
URL https://www.ncbi.nlm.nih.gov/pubmed/25749042
edoc-URL https://edoc.unibas.ch/61899/
Full Text on edoc No
Digital Object Identifier DOI 10.18632/oncotarget.3363
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/25749042
ISI-Number WOS:000352793000070
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.369 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
25/04/2024